This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Taiwan Advance Bio-Pharmaceutical's Median PS Value or its related term are showing as below:
ROCO:4186'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35 Med: 0.52 Max: 0.58
Current: 0.37
During the past 13 years, the highest Price to Median PS Value of Taiwan Advance Bio-Pharmaceutical was 0.58. The lowest was 0.35. And the median was 0.52.
ROCO:4186's Price-to-Median-PS-Value is ranked better than 75.81% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs ROCO:4186: 0.37
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Taiwan Advance Bio-Pharmaceutical's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
10.15
/
27.80
=
0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical Median PS Value Related Terms
Taiwan Advance Bio-Pharmaceutical Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical Median PS Value Chart
ROCO:4186 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.8574.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Median PS Value of NT$27.80 as of Jul. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. This is 5246% above median its historical median of 0.52. Over the past decade, Taiwan Advance Bio-Pharmaceutical's Median PS Value has ranged from 0.35 to 0.58. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #67 out of 277 companies in the Biotechnology industry, placing it in the top 24.2%.
Is Taiwan Advance Bio-Pharmaceutical's Median PS Value too high?
Taiwan Advance Bio-Pharmaceutical's current Median PS Value of NT$27.80 is 5246% above median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.58. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #67 out of 277 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #67 out of 277 companies for Median PS Value. This places Taiwan Advance Bio-Pharmaceutical in the top 24% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.63. Historically, Taiwan Advance Bio-Pharmaceutical's own Median PS Value has ranged from 0.35 to 0.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current Median PS Value is NT$27.80, which is 5246% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.88, compared to a current price of NT$10.15 — trading 43.2% below its estimated fair value. The current Median PS Value is NT$27.80, which is 5246% above median its 10-year median of 0.52. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Median PS Value is NT$27.80 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.15 is trading 43.2% below its estimated GF Value™ of NT$17.88.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
Median PS Value: NT$27.80 (5246% above median its 10-year median of 0.52)
GF Value™: NT$17.88 vs. price of NT$10.15 (43.2% below fair value)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score
Get the complete analysis for ROCO:4186
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
